Compare $OTLC vs $TOVX | Chartloom

Compare

$OTLC vs $TOVX

Oncotelic Therapeutics Inc · Theriva Biologics Inc

OTLC

Oncotelic Therapeutics Inc

TOVX

Theriva Biologics Inc

Compare $OTLC vs $TOVX

Comparing Oncotelic Therapeutics Inc and Theriva Biologics Inc

OTLCOncotelic Therapeutics Inc

TOVXTheriva Biologics Inc

OTLCOncotelic Therapeutics Inc

Market cap

$9M

P/E (TTM)

0.04x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-74.0%

52W performance

-76.9%

FCF yield

-16.5%

TOVXTheriva Biologics Inc

Market cap

$10M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-16.5%

52W performance

-51.8%

FCF yield

-128.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

OTLC

TOVX

Detailed metrics comparison

OTLC

Oncotelic Therapeutics Inc

TOVX

Theriva Biologics Inc

Market Cap

OTLC$9M

TOVX$10M

Enterprise Value

OTLC$23M

TOVX$275K

Price

OTLC$0.02

TOVX$0.22

P/E Ratio

OTLC0.04x

TOVXN/A

P/S Ratio

OTLC36.91x

TOVX33.19x

EV/Sales

OTLC91.75x

TOVX0.92x

EV/EBITDA

OTLC0.00x

TOVX0.00x

P/B Ratio

OTLC0.04x

TOVX0.85x

P/FCF Ratio

OTLCN/A

TOVXN/A

EV/FCF

OTLC-15.05x

TOVX-0.02x

PEG Ratio

OTLCN/A

TOVXN/A

Forward P/E (NTM)

OTLCN/A

TOVXN/A

Forward P/S (NTM)

OTLCN/A

TOVXN/A

Revenue (TTM)

OTLC$250K

TOVX$300K

Revenue Growth (YoY)

OTLCN/A

TOVXN/A

Forward Rev Growth

OTLC0.0%

TOVX20375.2%

Gross Margin (TTM)

OTLC83.1%

TOVX71.5%

Operating Margin (TTM)

OTLC0.0%

TOVX0.0%

EBITDA Margin (TTM)

OTLC-1545.3%

TOVX-3940.7%

Net Margin (TTM)

OTLC99875.6%

TOVX-4376.0%

FCF Margin (TTM)

OTLC-609.8%

TOVX-4254.7%

Net Income (TTM)

OTLC$250M

TOVX$-13M

FCF (TTM)

OTLC$-2M

TOVX$-13M

EPS (TTM)

OTLC$0.53

TOVX-$0.29

ROE (TTM)

OTLC139.7%

TOVX-9349.0%

ROA (TTM)

OTLC91.8%

TOVX-3269.0%

ROIC (TTM)

OTLC129.6%

TOVX-8231.0%

Cash

OTLC$186K

TOVX$11M

Debt

OTLC$14M

TOVX$2M

Net Cash/Debt

OTLC$-14M

TOVX$10M

Current Ratio (TTM)

OTLC0.08x

TOVX1.13x

Quick Ratio (TTM)

OTLC0.01x

TOVX1.09x

Debt/Equity (TTM)

OTLC0.05x

TOVX0.14x

Debt/Assets (TTM)

OTLC0.0%

TOVX0.0%

Interest Coverage (TTM)

OTLCN/A

TOVXN/A

Net Debt/EBITDA (TTM)

OTLC0.00x

TOVX0.00x

Beta

OTLC-0.07

TOVX1.25

52W Performance

OTLC-76.9%

TOVX-51.8%

YTD Performance

OTLC-74.0%

TOVX-16.5%

% from 52W High

OTLC-81.1%

TOVX-74.8%

% from 52W Low

OTLC4.0%

TOVX35.6%

Asset Turnover (TTM)

OTLC0.00x

TOVX0.01x

FCF Yield (TTM)

OTLC-16.5%

TOVX-128.2%

Earnings Yield (TTM)

OTLC2706.0%

TOVX-131.8%

Dividend Yield (TTM)

OTLCN/A

TOVXN/A

Rule of 40

OTLC-609.8

TOVX-4,254.7

EV/GP/RG

OTLCN/A

TOVX0.00

Ticker research

View OTLC research View TOVX research

Metric	OTLC Oncotelic Therapeutics Inc	TOVX Theriva Biologics Inc
Market & Valuation
Market Cap	$9M	$10M
Enterprise Value	$23M	$275K
Price	$0.02	$0.22
P/E Ratio	0.04x	N/A
P/S Ratio	36.91x	33.19x
EV/Sales	91.75x	0.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.04x	0.85x
P/FCF Ratio	N/A	N/A
EV/FCF	-15.05x	-0.02x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$250K	$300K
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	20375.2%
Profitability
Gross Margin (TTM)	83.1%	71.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1545.3%	-3940.7%
Net Margin (TTM)	99875.6%	-4376.0%
FCF Margin (TTM)	-609.8%	-4254.7%
Net Income (TTM)	$250M	$-13M
FCF (TTM)	$-2M	$-13M
EPS (TTM)	$0.53	-$0.29
ROE (TTM)	139.7%	-9349.0%
ROA (TTM)	91.8%	-3269.0%
ROIC (TTM)	129.6%	-8231.0%
Financial Health
Cash	$186K	$11M
Debt	$14M	$2M
Net Cash/Debt	$-14M	$10M
Current Ratio (TTM)	0.08x	1.13x
Quick Ratio (TTM)	0.01x	1.09x
Debt/Equity (TTM)	0.05x	0.14x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.07	1.25
52W Performance	-76.9%	-51.8%
YTD Performance	-74.0%	-16.5%
% from 52W High	-81.1%	-74.8%
% from 52W Low	4.0%	35.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-16.5%	-128.2%
Earnings Yield (TTM)	2706.0%	-131.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-609.8	-4,254.7
EV/GP/RG	N/A	0.00
Ticker research	View OTLC research	View TOVX research

Valuation

P/E Ratio

OTLC

0.04x

P/S Ratio

TOVX

33.19x

OTLC

36.91x

EV/FCF

OTLC

-15.05x

TOVX

-0.02x

Growth & revenue

Forward Revenue Growth

TOVX

20375.2%

OTLC

0.0%

Profitability & performance

Gross Margin

OTLC

83.1%

TOVX

71.5%

ROE

OTLC

139.7%

TOVX

-9349.0%

FCF Yield %

OTLC

-16.5%

TOVX

-128.2%

52-Week Performance

TOVX

-51.8%

OTLC

-76.9%

Detailed metrics comparison

OTLC

Oncotelic Therapeutics Inc

TOVX

Theriva Biologics Inc

Market Cap

OTLC$9M

TOVX$10M

Enterprise Value

OTLC$23M

TOVX$275K

Price

OTLC$0.02

TOVX$0.22

P/E Ratio

OTLC0.04x

TOVXN/A

P/S Ratio

OTLC36.91x

TOVX33.19x

EV/Sales

OTLC91.75x

TOVX0.92x

EV/EBITDA

OTLC0.00x

TOVX0.00x

P/B Ratio

OTLC0.04x

TOVX0.85x

P/FCF Ratio

OTLCN/A

TOVXN/A

EV/FCF

OTLC-15.05x

TOVX-0.02x

PEG Ratio

OTLCN/A

TOVXN/A

Forward P/E (NTM)

OTLCN/A

TOVXN/A

Forward P/S (NTM)

OTLCN/A

TOVXN/A

Revenue (TTM)

OTLC$250K

TOVX$300K

Revenue Growth (YoY)

OTLCN/A

TOVXN/A

Forward Rev Growth

OTLC0.0%

TOVX20375.2%

Gross Margin (TTM)

OTLC83.1%

TOVX71.5%

Operating Margin (TTM)

OTLC0.0%

TOVX0.0%

EBITDA Margin (TTM)

OTLC-1545.3%

TOVX-3940.7%

Net Margin (TTM)

OTLC99875.6%

TOVX-4376.0%

FCF Margin (TTM)

OTLC-609.8%

TOVX-4254.7%

Net Income (TTM)

OTLC$250M

TOVX$-13M

FCF (TTM)

OTLC$-2M

TOVX$-13M

EPS (TTM)

OTLC$0.53

TOVX-$0.29

ROE (TTM)

OTLC139.7%

TOVX-9349.0%

ROA (TTM)

OTLC91.8%

TOVX-3269.0%

ROIC (TTM)

OTLC129.6%

TOVX-8231.0%

Cash

OTLC$186K

TOVX$11M

Debt

OTLC$14M

TOVX$2M

Net Cash/Debt

OTLC$-14M

TOVX$10M

Current Ratio (TTM)

OTLC0.08x

TOVX1.13x

Quick Ratio (TTM)

OTLC0.01x

TOVX1.09x

Debt/Equity (TTM)

OTLC0.05x

TOVX0.14x

Debt/Assets (TTM)

OTLC0.0%

TOVX0.0%

Interest Coverage (TTM)

OTLCN/A

TOVXN/A

Net Debt/EBITDA (TTM)

OTLC0.00x

TOVX0.00x

Beta

OTLC-0.07

TOVX1.25

52W Performance

OTLC-76.9%

TOVX-51.8%

YTD Performance

OTLC-74.0%

TOVX-16.5%

% from 52W High

OTLC-81.1%

TOVX-74.8%

% from 52W Low

OTLC4.0%

TOVX35.6%

Asset Turnover (TTM)

OTLC0.00x

TOVX0.01x

FCF Yield (TTM)

OTLC-16.5%

TOVX-128.2%

Earnings Yield (TTM)

OTLC2706.0%

TOVX-131.8%

Dividend Yield (TTM)

OTLCN/A

TOVXN/A

Rule of 40

OTLC-609.8

TOVX-4,254.7

EV/GP/RG

OTLCN/A

TOVX0.00

Ticker research

View OTLC research View TOVX research

Metric	OTLC Oncotelic Therapeutics Inc	TOVX Theriva Biologics Inc
Market & Valuation
Market Cap	$9M	$10M
Enterprise Value	$23M	$275K
Price	$0.02	$0.22
P/E Ratio	0.04x	N/A
P/S Ratio	36.91x	33.19x
EV/Sales	91.75x	0.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.04x	0.85x
P/FCF Ratio	N/A	N/A
EV/FCF	-15.05x	-0.02x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$250K	$300K
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	20375.2%
Profitability
Gross Margin (TTM)	83.1%	71.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1545.3%	-3940.7%
Net Margin (TTM)	99875.6%	-4376.0%
FCF Margin (TTM)	-609.8%	-4254.7%
Net Income (TTM)	$250M	$-13M
FCF (TTM)	$-2M	$-13M
EPS (TTM)	$0.53	-$0.29
ROE (TTM)	139.7%	-9349.0%
ROA (TTM)	91.8%	-3269.0%
ROIC (TTM)	129.6%	-8231.0%
Financial Health
Cash	$186K	$11M
Debt	$14M	$2M
Net Cash/Debt	$-14M	$10M
Current Ratio (TTM)	0.08x	1.13x
Quick Ratio (TTM)	0.01x	1.09x
Debt/Equity (TTM)	0.05x	0.14x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.07	1.25
52W Performance	-76.9%	-51.8%
YTD Performance	-74.0%	-16.5%
% from 52W High	-81.1%	-74.8%
% from 52W Low	4.0%	35.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-16.5%	-128.2%
Earnings Yield (TTM)	2706.0%	-131.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-609.8	-4,254.7
EV/GP/RG	N/A	0.00
Ticker research	View OTLC research	View TOVX research